Jian Guan

Abstract 6741: Tertiary lymphoid structure (TLS)-associated immune circuits define response to durvalumab, trastuzumab, and pertuzumab (DTP) in HER2-enriched early breast cancer

Mailin Li, Xen Ping Hoi, Jenying Deng, Junjun Zheng et autres

Abstract Background: Chemotherapy-free regimens combining HER2-targeted therapy with immune checkpoint blockade are emerging as promising strategies in HER2-Enriched breast cancer. In our Phase II trial of durvalumab, trastuzumab, and pertuzumab (DTP), ER-negative, PR-negative, HER2-Enriched tumors (BluePrint®) achieved a 49% Pathologic Complete Response …

us (code pays fourni par la source)

Abstract PS3-11-20: Tumor-intrinsic signatures associated with response to chemotherapy-free HER2/PD-L1 blockade in HER2-enriched early breast cancer

M. Li, Jenying Deng, Xen Ping Hoi, J. Zheng et autres

Abstract Background: HER2-positive breast cancers have demonstrated sensitivity to de-escalated regimens combining HER2-targeted therapy with immune checkpoint inhibition. In our recent Phase II trial evaluating a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP), we observed a 49% pathologic complete response (pCR) …

us (code pays fourni par la source)

A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy.

Zainub Ajmal, Jian Guan, Jitesh Joshi, Eric Bernicker et autres

8551 Background: Interleukin-12 (IL-12) is a cytokine that enhances anti-tumor immunity via interferon-gamma release and has demonstrated synergistic effects with immune checkpoint inhibitors (ICIs) in immunoquiescent tumors. We report results of phase I trial of intratumoral adenovirus-interleukin-12(IT-ADV/IL-12)plus atezolizumab in metastatic NSCLC patients …

us (code pays fourni par la source)

Neighborhood Walkability Is Associated With Lower Burden of Cardiovascular Risk Factors Among Cancer Patients

Nwabunie Nwana, Omar Mohamed Makram, Juan Nicolás, Alan Pan et autres

Background: Modifiable cardiovascular risk factors constitute a significant cause of cardiovascular disease and mortality among patients with cancer. Recent studies suggest a potential link between neighborhood walkability and favorable cardiovascular risk factor profiles in the general population. Objectives: This study aimed to …

us (code pays fourni par la source)

Abstract CT029: Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial

Jian Guan, Kai Sun, Dharamvir Jain, Sunil Mathur et autres

Abstract Background: High risk HER2-positive early breast cancer (EBC) patients are traditionally treated with neoadjuvant chemotherapy in combination with HER2-directed therapy. De-escalation approaches are being studied as benefits of chemotherapy in the HER2-enriched subset of EBC, but they have been inconclusive thus …

us (code pays fourni par la source)

Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.

Jian Guan, Shubham Adroja, Zainub Ajmal, Yuan Gao et autres

85 Background: Relugolix is the first oral GNRH antagonist approved by the FDA in 2021 for the treatment of advanced prostate cancer (PCa). Approval was based on HERO study, which showed a rapid and sustained testosterone suppression superior to that of Leuprolide …

us (code pays fourni par la source)

A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer

Jian Guan, Kai Sun, Carlo Guerrero, Junjun Zheng et autres

us (code pays fourni par la source)

Clinical outcomes of patients with early-stage epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who underwent reflex molecular testing.

Ryan Blair Kieser, Ethan Burns, Zimu Gong, Jian Guan et autres

e20531 Background: One-third of patients with newly diagnosed non-small cell lung cancer (NSCLC) present at an early stage. Surgical resection remains the standard of care for medically fit patients. Adjuvant chemotherapy has shown benefit in stage II and III disease, but with …

us (code pays fourni par la source)

Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.

Jian Guan, Bin S. Teh, Amy C Schefler, Eric Bernicker

e21507 Background: Metastatic uveal melanoma carries a poor prognosis, especially for patients who are not eligible for Tebentafusp. Unlike cutaneous melanoma, checkpoint inhibitors have limited effect on uveal melanoma. The observation of Abscopal effect has inspired this study of adding radiotherapy to …

us (code pays fourni par la source)

The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.

Mengni Guo, Jieying Liu, Zohaib Ahmed, James Yu et autres

2525 Background: Immune checkpoint inhibitors (ICIs) can cause a variety of inflammatory autoimmune tissue damage, referred to as immune-related adverse events (irAEs). COVID-19 is associated with increased amounts of proinflammatory cytokines, which may synergistically affect the outcome of irAEs. Data are limited …

us (code pays fourni par la source)

Prognostic value of molecular response via ctDNA measurement in predicating response of systemic therapy in patients with advanced solid cancer.

Abdullah Esmail, Jian Guan, Jiaqiong Xu, Hadeel Al‐Rawi et autres

e13001 Background: Molecular profiling of cancer can guide treatment decision, monitor response and predict clinical outcome in the era of precision medicine and individualized treatment. Emerging evidence has suggested that ctDNA change correlates with treatment response and predates radiological relapse. Thus, we …

us (code pays fourni par la source)